| Compound Information | SONAR Target prediction |
| Name: | FOSCARNET SODIUM |
| Unique Identifier: | SPE01502019 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 191.951 g/mol |
| X log p: | -2.608 (online calculus) |
| Lipinksi Failures | 0 |
| TPSA | 113.13 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 5 |
| Rotatable Bond Count: | 1 |
| Canonical Smiles: | [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O |
| Source: | synthetic |
| Therapeutics: | antiviral |
| Generic_name: | Foscarnet |
| Chemical_iupac_name: | phosphonomethanoic acid |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA449706 |
| Kegg_compound_id: | C07623 |
| Drugbank_id: | APRD00669 |
| Melting_point: | 88.06 oC |
| H2o_solubility: | Complete |
| Cas_registry_number: | 63585-09-1 |
| Drug_category: | Antivirals; Reverse Transcriptase Inhibitors; ATC:J05AD01 |
| Indication: | For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. |
| Pharmacology: | Foscarnet is an organic analogue of inorganic pyrophosphate that inhibits replication of herpes viruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to foscarnet. However, acyclovir or ganciclovir resistant mutants with alterations in the viral DNA polymerase may be resistant to foscarnet and may not respond to therapy with foscarnet. The combination of foscarnet and ganciclovir has been shown to have enhanced activity in vitro. |
| Mechanism_of_action: | Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. |
| Organisms_affected: | Human herpes viruses |
| Found: 8 active | as graph: single | with analogs | 1 2 3 4 5 6 7 8 Next >> |
| Species: | 4932 |
| Condition: | SPE01503602 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.3981±0 |
| Normalized OD Score: sc h | 1.7812±0 |
| Z-Score: | 8.1982±0 |
| p-Value: | 2.43962e-16 |
| Z-Factor: | 0.650121 |
| Fitness Defect: | 35.9495 |
| Bioactivity Statement: | Active |
| ps |
| DBLink | Rows returned: 11 | << Back 1 2 |
| 3957967 | azanide; (oxido-oxoniocarbonyl-phosphoryl)oxidanium; platinum(+4) cation |
| 4361452 | (oxido-oxoniocarbonyl-phosphoryl)oxidanium |
| 4488958 | trisodium phosphonatoformate |
| 4567503 | phosphonatoformic acid |
| 6711435 | azanide; (hydroxy-oxido-phosphoryl)formate; platinum(+4) cation |
| internal high similarity DBLink | Rows returned: 0 |
| active | Cluster 3362 | Additional Members: 1 | Rows returned: 0 |
Service provided by the
Mike Tyers Laboratory